The internet-connected TV platform has multiple headwinds to overcome if this stock is going to end up working for shareholders in the long run. Read More...
Motley Fool
This Growth Stock’s Jaw-Dropping Run-Up Is Smashing Tesla’s
Tesla stock might’ve made investors rich over the last few years, gaining more than 599.9% since late 2019, but 2022 has been a rough year for the company, with its shares losing slightly more than half their value amid a punishing bear market. In contrast, a little-known biotech called Catalyst Pharmaceuticals (NASDAQ: CPRX) gained 303% in 2022, and there’s reason to believe that there’s still plenty of upside to come. In fact, the company is ripe for a purchase, and there’s reason to believe it might continue to smash Tesla’s return in 2023 and beyond.
Add Comment